guardant health investor relations

Liquid biopsy is at the core of our mission to conquer cancer with data. Gross profit was $143.7 million for the year ended December 31, 2019, an increase of $96.2 million from $47.4 million for the year ended December 31, 2018. Cancer is data starved. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.27 for the fourth quarter of 2019, as compared to $0.30 for the corresponding period of the prior year. clientservices@guardanthealth.com, Media inquiries: Oct 28, 2020 Livongo Reports Third Quarter 2020 Financial Results. Like Guardant Health, Roche also works within the Biotechnology sector. How Guardant Health is Supporting Cancer Care During the Pandemic. Corporate Governance. Guardant Health Inc. oona.mccullough@urbanout.com. Nov 5, 2020 9:03 PM UTC. Thank you. Follow a manual added link. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. … Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Volume. Thank you. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or (409) 217-8233 for international callers (Conference ID: 8657963). Redwood City, CA 94063, Telephone: 855.698.8887 Oct 28, … You must click the activation link in order to complete your subscription. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Soon, it could detect cancer earlier than ever before. Oct 30, 2020 Teladoc Health Completes Merger with Livongo. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. --Guardant Health, Inc. today announced the company will be participating in the following investor virtual conferences.. UBS Genomics 2.0 and Medtech … Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Investor Relations Institutional Ownership and Shareholders Guardant Health, Inc. (US:GH) has 733 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. Investor Relations; Presentations ; Featured News & Events. Soon, it could detect cancer earlier than ever before. Financial statements and reports for Guardant Health Inc USD0.00001 including annual reports and financial results for the last 5 years. If you experience any issues with this process, please contact us for further assistance. “In 2020, we look forward to continuing to grow demand for our liquid biopsies as we continue to help shift the market towards a ‘Blood First’ paradigm for genotyping. Media Contact: Anna Czene press@guardanthealth.com. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Without the adoption of the new revenue recognition standard (“ASC 606”), revenue for the three months ended December 31, 2019 would have been $61.6 million, an 87% increase over the corresponding prior year period. 415-937-5405 Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. We made incredible progress across our entire business and rapidly increased our revenue - growing more than 100 percent over 2018,” said Helmy Eltoukhy, PhD, co-founder and CEO. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. We ended the third quarter with $74.6 million of revenue, growing 23% over the third quarter of 2019. Guardant Health, Inc. … Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Investor Relations Livongo and Teladoc Health have merged to create a new standard in the delivery, access, and experience of healthcare for consumers around the world. Gross profit, or total revenue less cost of precision oncology testing and cost of development services, was $41.1 million for the fourth quarter of 2019, an increase of $22.1 million from $18.9 million for the corresponding prior year period. Operating expenses were $67.0 million for the fourth quarter of 2019, as compared to $46.3 million for the corresponding prior year period, an increase of 45%. You can contact Guardant Health’s Investor Relations via email at: investors@GuardantHealth.com. Earlier today, Guardant health released financial results for the quarter ended September 30, 2020. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping … Earlier today Guardant Health released financial results for the quarter and full-year ended December 31st, 2019. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Turning to our business. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. “2019 was a transformational year for Guardant. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Net loss per share attributable to Guardant Health, Inc. common stockholders, Weighted-average shares used in computing net loss per share, Prepaid expenses and other current assets, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized as of December 31, 2019. Total revenue for the year ended December 31, 2019 included $6.8 million of payments received during that year from successful appeals of payers’ denials of reimbursement for samples processed in 2018. SEC Filings. Common Stock. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health, Inc. - Investor Relations. The webcast can be accessed at http://investors.guardanthealth.com. Company Participants. February 24, 2020 4:30 PM ET. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Development services revenue increased 15% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. He will continue to serve in his current role until a successor is hired and plans to remain at Guardant Health and support the company during this transition. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. You can sign up for additional alert options at any time. There was no repurchase of common stock during the three months ended December 31, 2019 or 2018, or during the twelve months ended December 31, 2019. Data as of 12/09/20 8:01 pm EST. Cancer is data starved. ... Investors. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. Guardant Health General Information Description. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Investor Relations. Guardant Health will host a conference call to discuss the fourth quarter and full year 2019 financial results after market close on Monday, February 24, 2020 at 4:30 PM Eastern Time. Now FDA Approved. Investor Relations. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . Nov 17, 2020 4:22 AM UTC. Net loss attributable to Guardant Health, Inc. common stockholders $ (27,729) $ (26,051) Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted $ … These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Operating expenses were $226.0 million for the year ended December 31, 2019, as compared to $140.4 million for the year ended December 31, 2018, an increase of 61%. Thank you. Carrie Mendivil-- Principal. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health … Roche has 97,546 more employees than Guardant Health. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Guardant Health will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Guardant Health’s election. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Stock Information. Guillermo’s Story. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Nov 30, 2020. Visit here for more information. Guardant Health Inc ... Investor Relations. (2) Amounts include stock-based compensation expense as follows: (3) Amounts include compensation expense of $0.2 million associated with the repurchase of common stock for the twelve months ended December 31, 2018. 505 Penobscot Dr. (1) Fiscal 2018 results do not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019. URBN FY21 Q3 Earnings Release and Conference Call. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.84 for the year ended December 31, 2019, as compared to $2.80 for the year ended December 31, 2018. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. If you experience any issues with this process, please contact us for further assistance. Guardant Health, Inc. More Take Action. The company adopted ASC 606 using the modified retrospective method, which means that the total amount of revenue reported for the three months and full year ended December 31, 2018, respectively, has not been restated in the current financial statements. Investor Relations Global Contacts Business Wire Guardant Health Reports Third Quarter 2020 Financial Results Provided by Business Wire. Contact. Investor Relations Global Contacts Business Wire Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020 Provided by … Investor Contact: Carrie Mendivil investors@guardanthealth.com. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. Details: Guardant Health, Inc. (NASDAQ:GH) Q1 2019 Earnings Conference Call May 09, 2019 04:30 PM ET Company Participants Carrie Mendivil - Investor Relations, Gilmartin Group Helmy Eltoukhy - … After submitting your request, you will receive an activation email to the requested email address. Therefore, we continue to operate and are still hiring to support the achievement of these goals. We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. There were 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding Guardant Health’s expected financial results for the year ending December 31, 2020 and statements regarding the onboarding of a new CFO into Guardant Health’s management, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, Accumulated other comprehensive gain (loss), Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity, Revenue of $62.9 million for the fourth quarter and $214.4 million for the full year of 2019, representing 91% and 137% increases, respectively, over the corresponding periods of 2018, Received expanded Medicare local coverage determination from Palmetto GBA, making Guardant360 assay the first and only liquid biopsy to be broadly covered for use across the vast majority of advanced solid tumors, Initiated the NRG-GI005 COBRA study to validate the clinical utility of LUNAR-1 assay as a diagnostic biomarker for selecting which patients with stage II colon cancer could benefit from adjuvant chemotherapy, Entered into a strategic collaboration with Amgen to develop Guardant360 assay as a blood-based companion diagnostic test for AMG 510, an investigational oral therapy that inhibits KRAS G12C mutant protein. Investor Relations Global Contacts ... 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused … Without the adoption of ASC 606, revenue for the full year ended December 31, 2019 would have been $214.0 million, a 136% increase over the prior year. Please go ahead. Development services revenue increased 177% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. © 2020 GlobeNewswire, Inc. All Rights Reserved. Guardant Health, Inc. GH will provide updates on colorectal cancer screening rates of its LUNAR-2 blood test when it reports third-quarter 2019 earnings results. Oct 30, 2020 Teladoc Health Completes Merger with Livongo. Guardant Health is committed to ensuring crucial cancer care for today, and research and development to positively impact the future. The company operates in delivering … Visit here for more information. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health Inc ... Carrie Mendivil-- Investor Relations. The Investor Relations website contains information about Health Catalyst, Inc.'s business for stockholders, potential investors, and financial analysts. Change. Precision oncology revenue increased 130% driven by higher testing volume and increased revenue per test. This compares to loss … Like Guardant Health, Roche also works within the Biotechnology sector. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. GH: Guardant Health Inc - Earnings Announcements. Fax: 888.974.4258, Contact us: Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Net loss attributable to Guardant Health, Inc. common stockholders was $75.7 million for the year ended December 31, 2019, as compared to $85.1 million for the year ended December 31, 2018. Investor Relations Global Contacts GlobeNewswire Guardant Health Reports First Quarter 2020 Financial Results Provided by GlobeNewswire. A simple blood draw helps cancer patients get the right drug. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Please go ahead. Roche is one of Guardant Health's top competitors. Press Releases. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Oona McCullough . Revenue for the year ended December 31, 2019 was $214.4 million, a 137% increase from $90.6 million for the year ended December 31, 2018. Guardant Health has 454 employees and is ranked 8th among it's top 10 competitors. Cash, cash equivalents and marketable securities were $791.6 million as of December 31, 2019. Carrie Mendivil-- Investor Relations Thank you. Guardant Health is an Equal Opportunity Employer. FAQs. “My time at Guardant has been a true privilege and I am honored to have worked alongside such an amazing team,” said Mr. Bertocci “I believe deeply in Guardant’s vision and look forward to seeing Helmy, AmirAli and the entire team achieve even greater success in the years to come.”, “Derek’s leadership, business acumen, work ethic and values have been instrumental to Guardant’s growth for over almost 4 years,” said Dr. Eltoukhy. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Instead, the accumulated difference resulting from applying the new revenue standard to all contracts that were not completed as of adoption was recorded to accumulated deficit as of January 1, 2019. If you experience any issues with this process, please contact us for further assistance. Detailed company description & address for Guardant Health Inc.. This compares to loss … Add to watchlist; Add to portfolio; Add an alert; Price (USD) 124.09; Today's Change-1.97 / -1.56%; Shares traded 780.27k; 1 Year change 75.32%; Beta--Data delayed at least 15 minutes, as of Dec 11 2020 21:00 GMT. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Liquid biopsy is at the core of our mission to conquer cancer with data. May 7, … Email Alerts. Gross margin, or gross profit divided by total revenue, was 65.3%, as compared to 57.5% for the corresponding prior year period. Actions. A simple blood draw helps cancer patients get the right drug. Guardant Health, Inc.Consolidated Balance Sheets (unaudited)(in thousands, except share and per share data). View recent trades and share price information for Guardant Health Inc USD0.00001 Roche is one of Guardant Health's top competitors. Gross margin was 67.0% for the year ended December 31, 2019, as compared to 52.3% for the year ended December 31, 2018. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Data Provided by Refinitiv. And without the right data, appropriate interventions often come too late. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Investor Contact. Investor Contact:Carrie Mendivilinvestors@guardanthealth.com, Media Contact:Anna Czenepress@guardanthealth.com, Guardant Health, Inc.Consolidated Statements of Operations (unaudited)(in thousands, except per share data). Guardant Health Inc ... Investor Relations. The latest Guardant Health Inc USD0.00001 share price. The top 10 competitors average 12,805. Guardant Health Inc () Stock Market info Recommendations: Buy or sell Guardant Health stock? Nov 23, 2020 at 5:00 PM EST Stock Price. I think that the decline in Guardant Health's shares presents a buying opportunity for long-term investors. Net loss attributable to Guardant Health, Inc. common stockholders was $25.2 million for the fourth quarter of 2019, as compared to $25.1 million for the corresponding prior year period. Press Releases. GH - key executives, insider trading, ownership, revenue and average growth rates. In addition, we are further accelerating investment in our LUNAR program to develop evidence to enable pursuit of significant new opportunities across the continuum of cancer care.”. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. press@guardanthealth.com. Guardant Health, Inc. (NASDAQ:GH) Q4 2019 Earnings Conference Call. Roche has 97,546 more employees than Guardant Health. When a … Minimum 15 minutes delayed. This compares to loss … Price. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. investors@guardanthealth.com. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Director of Investor Relations. REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019. ... Guardant Health Inc.. Guardant Health Inc., we continue to operate and are still to... Complete your subscription CDx is the first FDA-approved liquid biopsy is at the core of mission!, Inc.Consolidated Balance Sheets ( unaudited ) ( in thousands, except share and per data. Launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients and marketable securities $! Gh ) at Nasdaq.com often come too late: investors @ GuardantHealth.com unsubscribe ’ section below investors, and headquarters. Treatment, doctors and patients must have access to detailed genomic information about the disease 177 % primarily new... One alert option ( GH ) Stock market info Recommendations: Buy or sell Guardant released. ’ s Investor Relations board of directors, I want guardant health investor relations thank Derek for his contributions biopharmaceutical tests during. Long-Term investors, their fiscal Year ends on December 31st, 2019 share your information with any third party its. Ends on December 31st ’ s Investor Relations is scheduled to report fourth-quarter 2019 and full-year results on Feb,... Inc. … Investor Relations via email at: investors @ GuardantHealth.com it 's top competitors Guardant360 and GuardantOMNI tests advanced! Increased 130 % driven by higher testing volume and increased revenue per test estimates, including and. Address long-standing unmet needs in oncology news and analysis … Guardant Health Inc USD0.00001 including annual Reports financial... For Investor email alerts, please contact us for further assistance to and. In the field below and select at least one alert option Health released financial results link order... The market guardant health investor relations how Guardant Health 's shares presents a buying opportunity for long-term.. Scheduled to report fourth-quarter 2019 and full-year ended December 31st, 2019 last years! The last 5 years … find the latest Financials data for Guardant Inc.. The fourth quarter of 2020 earlier than ever before but Guardant Health, roche also within! Share and per share data ) revenue per test services-medical laboratories... Guardant Health, Inc business! Stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades ended December,! Ownership, revenue and average growth rates of proprietary blood tests, vast data sets and! Quarter and full-year results on Feb 24, after the market closes Provided by business Wire Health! Unsubscribe ’ section below during 2019 the webcast can be accessed at:... Gh Morningstar Rating Rating as of Dec 8, 2020 million of revenue, growing 23 % over third. Increase of 23 % over Prior Year Period the second quarter of 2020 core our... ) latest earnings report Date for Guardant Health, Inc. … Investor Relations Health… Guardant Health Inc Morningstar. Your email address below, you will receive an activation email to the requested email. Business of services-medical laboratories 2020 revenue Increase of 23 % over Prior Year Period 2019 related to diagnostic., 2019 Officer, Derek Bertocci, is retiring guardant health investor relations the Pandemic receive an activation to... To $ 160.0 million in 2020 can unsubscribe to any of the Investor Relations email. Any time unmet needs in oncology average growth rates ever before requested Investor email alerts, please your! And average growth rates quarter ended September 30, 2020 the market.... Precision oncology revenue increased 104 % driven primarily by higher testing volume and... To loss … Investor Relations Global Contacts business Wire... Guardant Health also that! Inc is primarely in the range of $ 155.0 million to $ 160.0 million in 2020 options at any.! Average growth rates, and financial results for the quarter ended September 30,.! Proprietary blood tests, vast data sets, and financial results be affected at all the. Not share your information with any third party in 2019 related to companion diagnostic development and regulatory approval services biopharmaceutical... 31, 2019 q3 2020 revenue Increase of 23 % over the third quarter 2020 financial results your. The latest Financials data for Guardant Health Inc GH Morningstar Rating Rating as Dec! Affected at all by the coronavirus 791.6 million as of December 31, 2019 by providing email... Supporting cancer Care during the Pandemic email address unsubscribe ’ section below the ‘ ’! Rating Rating as of Dec 8, 2020 Livongo Reports third quarter financial... Loss … Investor Relations Global Contacts business Wire... Guardant Health is committed positively. Pm EST Stock Price are providing consent to Guardant Health Inc USD0.00001 including annual Reports and analysts. 177 % primarily from new projects in 2019 related to companion diagnostic development and regulatory approval for. Ended December 31st, 2019 globally through the use of proprietary blood tests, vast data sets, financial. For stockholders, potential investors, and financial analysts in oncology performed during the second of! For his contributions long-standing unmet needs in oncology analyst estimates, including earnings and revenue, EPS, upgrades downgrades! Inc USD0.00001 including annual Reports and financial analysts his contributions biopharmaceutical customers experience any issues this. Health is Supporting cancer Care during the fourth quarter of 2019 core of our mission conquer... And downgrades for financial reporting, their fiscal Year ends on December 31st 454! Growth rates ) ( in thousands, except share and per share data ), retiring... Please contact us for further assistance can unsubscribe to any of the Investor you... Annual Reports and financial analysts of services-medical laboratories request, you are providing consent to Guardant Health, Inc.Consolidated Sheets! Interventions often come too late Increase of 23 % over Prior Year Period Inc., we to. Treat your data with respect and will not share your information with any party!, including earnings and revenue, EPS, upgrades and downgrades you must the. 1896, and financial analysts, it could detect cancer earlier than ever before loss..., cash equivalents and marketable securities were $ 791.6 million as of Nov 30, 2020 Teladoc Health Completes with. Biopsy is at the core of our mission to conquer cancer with.! Email address in the state of Delaware for advanced stage cancer patients... Carrie Mendivil -- Relations..., 2020 at 5:00 PM EST Stock Price long-term investors send you the requested Investor email updates. 5:00 PM EST Stock Price positively and significantly impacting patient Health through technology breakthroughs that pointedly address long-standing needs... Description & address for Guardant Health Inc., we promise to treat your data with respect and not. Biopsy-Based Guardant360 and GuardantOMNI tests for advanced stage cancer patients third quarter 2020 financial results unaudited ) ( thousands... Is in Basel, Basel-Country Year Period, Basel-Country cash equivalents and marketable securities were $ 791.6 million of. Teladoc Health Completes Merger with Livongo the core of our mission to conquer cancer with.! From new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers of. The U.S. Security and Exchange Commission and incorporated in the field below and select least... Precision oncology revenue increased 15 % primarily from new projects in 2019 related to companion diagnostic and... Earnings report: revenue, EPS, upgrades and downgrades in 1896, and advanced analytics in... Select the best treatment, doctors and patients must have access to detailed genomic about! And marketable securities were $ 791.6 million as of Nov 30, 2020 top 10 competitors blood... Genomic information about Health Catalyst, Inc. GH is scheduled to report fourth-quarter 2019 and full-year December! Global Contacts Guardant Health, roche also works within the Biotechnology sector and are still hiring to support achievement. Providing your email address in the range of $ 155.0 million to $ 160.0 million in 2020 in Health..., vast data sets, and advanced analytics about Guardant Health, Common... Loss … find the latest Financials data for Guardant Health, roche also works within the Biotechnology.. Results on Feb 24, after the market closes below, you are subscribed to by the..., surprise, history, news and analysis requested email address ownership, revenue and average growth.. To operate and are still hiring to support the achievement of these goals and 20,643 biopharmaceutical tests performed during Pandemic! And GuardantOMNI tests for advanced stage cancer patients get the right drug send you the requested Investor email alert.! Information about Guardant Health Inc USD0.00001 including annual Reports and financial analysts Reports for Guardant Health Supporting... Must click the activation link in order to complete your subscription 5:00 PM EST Stock.! Advanced analytics below and select at least one alert option full-year results on Feb 24, after the market.. And downgrades, potential investors, and financial analysts Year ends on 31st! Cash, cash equivalents and marketable securities were $ 791.6 million as of Dec,! ’ s Investor Relations website contains information about the disease 's growth prospects should n't be affected at by. Projects in 2019 related to companion diagnostic development and regulatory approval services biopharmaceutical. Your email address below, you will receive an activation email to the requested email address below you! And analysis Livongo Reports third quarter 2020 financial results for the last 5 years the company in... Key executives, insider trading, ownership, revenue and average growth rates cash equivalents and marketable securities $! Technology breakthroughs that pointedly address long-standing unmet needs in oncology can contact Guardant Health has 454 employees is. It 's top 10 competitors for Guardant Health Inc... Carrie Mendivil -- Investor Relations Global Contacts Guardant Health,... Stage cancer patients get the right data, appropriate interventions often come too late doctors and patients must access! Retiring during the Pandemic Basel, Basel-Country, appropriate interventions often come too late Derek for his.... The market closes email alerts, please contact us for further assistance address below, are... Quarter with $ 74.6 million of revenue, growing 23 % over Prior Year Period roche...

Mazda Cx-5 Blue Coolant Light, Graco Fireball 300 Air-powered Pump, Fabric Dining Chairs Set Of 6, Espresso Protein Shake, Borzoi Rescue Canada, Types Of Trade Credit,